CITIUS ONCOLOGY, INC.
Close on Oct 19, 2026
- Market cap
- $76.65M
- P/E (TTM)
- –
- Dividend yield
- –
About Citius Oncology
Pharmaceutical Preparations, SIC 2834
Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. Its primary approved product is LYMPHIR (denileukin diftitox-cdxl), an engineered interleukin-2 diphtheria toxin fusion protein. The medication is designed for adult patients suffering from persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. LYMPHIR operates through a dual mechanism that delivers cytotoxic diphtheria toxin directly to cells expressing interleukin-2 receptors while simultaneously depleting immunosuppressive regulatory T cells.
The company focuses its direct commercialization activities within the United States, utilizing a specialized oncology sales team aimed primarily at major cancer centers. For markets outside the United States, the business establishes international commercial partnerships. Headquartered in Cranford, New Jersey, the company also evaluates combination immuno-oncology therapies through clinical investigations in clinical trial sites across the United States.
Summary of the business section of Citius Oncology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CITIUS ONCOLOGY, INC.
- Founded
- 2021
- Headquarters
- Cranford, NJ
- Address
- 11 Commerce Drive, 1st Floor 07016
- Phone
- (908) 967-6677
- Website
- citiusonc.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- September 30
- Auditor
- Wolf & Company, P.C., Boston, Massachusetts
Stock & identifiers
- Ticker
- CTOR
- Exchange
- Nasdaq
- IPO date
- Oct 14, 2022
- Shares outstanding
- 93M, Aug 13, 2026
- Public float
- $5.10M, Mar 31, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 43-for-3, Dec 27, 2024
- SEC CIK
- 1851484
- CUSIP
- 17331Y109
- ISIN
- US17331Y1091
- EIN
- 99-4362660
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Leonard L. Mazur | Chief Executive Officer, Director | 1,700,000 |
| Myron Z. Holubiak | Secretary, Director | 950,000 |
| Jaime Bartushak | Chief Financial Officer | 825,000 |
| Myron Czuczman | Chief Medical Officer | 825,000 |
| Jonathan Peri | Director | 0 |
| Dennis M. McGrath | Director | 300,000 |
| Robert Joseph Smith | Director | 300,000 |
| Suren G. Dutia | Director | 300,000 |
| Eugene Myron Holuka | Director | 300,000 |
| Carol Webb | Director | 300,000 |
| Joel David Mayersohn | Director | 321,228 |
Corporate history
Events identified from SEC filings